Arizona State Retirement System Purchases New Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Arizona State Retirement System purchased a new stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 9,512 shares of the company’s stock, valued at approximately $237,000.

A number of other institutional investors have also made changes to their positions in KYMR. Bank of New York Mellon Corp raised its holdings in shares of Kymera Therapeutics by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 686,194 shares of the company’s stock valued at $29,041,000 after buying an additional 155,476 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Kymera Therapeutics by 57.0% during the 1st quarter. MetLife Investment Management LLC now owns 19,228 shares of the company’s stock worth $814,000 after purchasing an additional 6,981 shares during the last quarter. Rhumbline Advisers raised its holdings in Kymera Therapeutics by 7.4% during the 1st quarter. Rhumbline Advisers now owns 36,208 shares of the company’s stock worth $1,532,000 after purchasing an additional 2,481 shares during the last quarter. BlackRock Inc. raised its holdings in Kymera Therapeutics by 0.6% during the 1st quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock worth $144,698,000 after purchasing an additional 21,544 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Kymera Therapeutics by 266.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 237,731 shares of the company’s stock worth $10,060,000 after purchasing an additional 172,839 shares during the last quarter.

Insider Buying and Selling

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 1,370 shares of the company’s stock in a transaction that occurred on Thursday, March 2nd. The stock was sold at an average price of $31.00, for a total transaction of $42,470.00. Following the completion of the transaction, the chief financial officer now owns 104,568 shares of the company’s stock, valued at approximately $3,241,608. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 17.01% of the stock is owned by company insiders.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $29.30 on Wednesday. The business has a 50 day simple moving average of $30.53 and a 200 day simple moving average of $30.63. Kymera Therapeutics, Inc. has a 52-week low of $13.15 and a 52-week high of $39.85. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -10.21 and a beta of 1.71.

Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last posted its earnings results on Thursday, May 4th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.01). Kymera Therapeutics had a negative return on equity of 34.15% and a negative net margin of 340.80%. The business had revenue of $9.47 million for the quarter, compared to the consensus estimate of $14.15 million. During the same period in the previous year, the company posted ($0.71) earnings per share. Kymera Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, analysts predict that Kymera Therapeutics, Inc. will post -2.66 EPS for the current year.

Analysts Set New Price Targets

KYMR has been the subject of several recent research reports. Raymond James raised Kymera Therapeutics from a “market perform” rating to an “outperform” rating in a report on Thursday, May 4th. Credit Suisse Group upped their price target on Kymera Therapeutics from $32.00 to $39.00 and gave the company a “neutral” rating in a research note on Friday, February 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price target on shares of Kymera Therapeutics in a research note on Friday, February 24th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $47.22.

About Kymera Therapeutics

(Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.